Treatment of Inflammatory Bowel Disease with Biologics

150

Steenholdt et al. [

57

]

CD: 53UC: 28

Retrospective 86% concomitant IMM (CD and UC)

CD: 39% (1 year), 88% (10 years)

CD: longer disease duration

Not available

96% (CD)

UC: 25% (1 year), 60% (4.5 years)

71% (UC)

Gisbert et al. [^40

]

27 studies

Systematic review, Meta-analysis

CD: 38% (0.5 year), 40% (1 year), 49% (>2.1 years)

Younger age

80%

Smoking statusLonger disease duration

UC: 28% (1 year)

Fistulizing perianal CDLow hemoglobinHigh C-reactive proteinHigh fecal calprotectinAbsence of mucosal healing

Authors

Number of participants (

n)

Study design

Relapse rate

Significant predictors of relapse

Predictors evaluated but not found to be significant

Recapture rate

Table 10.1

(continued)

H.H. Shim and C.H. Seow